In attack therapy from 900 to 1200 mg / day in three oral administrations. In maintenance therapy from 300 to 600 mg / day in one or more oral administration.

Prostate strips (6 x 3 x 3 mm) were mounted in 10-ml aerated (95% O2-5% CO2) tissue baths (Föhr Medical Instruments, Seeheim, Germany), containing Krebs-Henseleit solution (37°C, pH 7.4). Preparations were stretched to 0.5 g and left to equilibrate for 45 min. In the initial phase of the equilibration period, spontaneous decreases in tone are usually observed. Therefore, tension was adjusted three times during the equilibration period, until a stable resting tone (0.5 g) was attained. After the equilibration period, maximum contraction induced by 80 mM KCl (Krebs-Henseleit solution where NaCl was exchanged by KCl) was assessed. Subsequently, chambers were washed three times with Krebs-Henseleit solution for a total of 30 min. Cumulative concentration response curves for U46619, norepinephrine, or phenylephrine were created after addition of TXA2-R antagonists (Picotamide 0.1-30mkM) or solvent [dimethylsulfoxide (DMSO)]. Frequency response curves induced by electric field stimulation (EFS) were created before and after addition of antagonists or DMSO. Antagonists or DMSO were applied 45 min before concentration or frequency response curves.